Literature DB >> 15927468

Discovery and synthesis of a novel and selective drug-like P2X(1) antagonist.

S Jaime-Figueroa1, R Greenhouse, F Padilla, M P Dillon, J R Gever, A P D W Ford.   

Abstract

Although there is extensive literature to indicate that many different types of P2 purinoceptors are present in the lower urinary tract, the physiological role of these receptors in micturition is still uncertain. In part, this uncertainty has been caused by a lack of P2 subtype selective ligands. In this paper we report the discovery, gram scale synthesis, and binding results for 1, the first potent, drug-like, selective P2X(1) receptor antagonist described. Compound 1 was shown to be more than 30-fold selective over other purinergic receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15927468     DOI: 10.1016/j.bmcl.2005.04.049

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  11 in total

1.  Development of a comprehensive set of P2 receptor pharmacological research compounds.

Authors:  R A Felix; S Martin; S Pinion; D J Crawford
Journal:  Purinergic Signal       Date:  2011-11-04       Impact factor: 3.765

Review 2.  Medicinal chemistry of adenosine, P2Y and P2X receptors.

Authors:  Kenneth A Jacobson; Christa E Müller
Journal:  Neuropharmacology       Date:  2015-12-12       Impact factor: 5.250

Review 3.  Pharmacology of P2X channels.

Authors:  Joel R Gever; Debra A Cockayne; Michael P Dillon; Geoffrey Burnstock; Anthony P D W Ford
Journal:  Pflugers Arch       Date:  2006-04-29       Impact factor: 3.657

Review 4.  Activation and regulation of purinergic P2X receptor channels.

Authors:  Claudio Coddou; Zonghe Yan; Tomas Obsil; J Pablo Huidobro-Toro; Stanko S Stojilkovic
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

5.  P2X1 Selective Antagonists Block HIV-1 Infection through Inhibition of Envelope Conformation-Dependent Fusion.

Authors:  Alexandra Y Soare; Hagerah S Malik; Natasha D Durham; Tracey L Freeman; Raymond Alvarez; Foramben Patel; Namita Satija; Chitra Upadhyay; Catarina E Hioe; Benjamin K Chen; Talia H Swartz
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

Review 6.  Agonists and antagonists for P2 receptors.

Authors:  Kenneth A Jacobson; Stefano Costanzi; Bhalchandra V Joshi; Pedro Besada; Dae Hong Shin; Hyojin Ko; Andrei A Ivanov; Liaman Mamedova
Journal:  Novartis Found Symp       Date:  2006

7.  Pharmacochemistry of the platelet purinergic receptors.

Authors:  Kenneth A Jacobson; Francesca Deflorian; Shilpi Mishra; Stefano Costanzi
Journal:  Purinergic Signal       Date:  2011-02-18       Impact factor: 3.765

Review 8.  The P2X1 receptor as a therapeutic target.

Authors:  Felix M Bennetts; Jesse I Mobbs; Sabatino Ventura; David M Thal
Journal:  Purinergic Signal       Date:  2022-07-11       Impact factor: 3.950

Review 9.  Purinoceptors as therapeutic targets for lower urinary tract dysfunction.

Authors:  Anthony P D W Ford; Joel R Gever; Philip A Nunn; Yu Zhong; Joseph S Cefalu; Michael P Dillon; Debra A Cockayne
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

10.  Stereoselective Syntheses and Application of Chiral Bi- and Tridentate Ligands Derived from (+)-Sabinol.

Authors:  Yerbolat Tashenov; Mathias Daniels; Koen Robeyns; Luc Van Meervelt; Wim Dehaen; Yerlan M Suleimen; Zsolt Szakonyi
Journal:  Molecules       Date:  2018-03-27       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.